Search Results
066 - Actinium Pharma's Transformative Radiation Treatment. KPTI's Selinexor Approved for DLBCL!
The SADAL study: selinexor for R/R DLBCL
Can older Refractory/Relapsed AML Patients Undergo Successful BMT without Entering CR First?
Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL
Actinium Pharmaceuticals | Compelling Results Enable Pivotal Phase III Trial
Selinexor for RRMM
Actinium Pharmaceuticals | Focused on Improving Cancer Patient Outcomes
Update on selinexor for myeloma and large cell lymphomas
Selinexor Combination Therapy for RRMM
Actinium Pharmaceuticals Webcast Presentation @ Lytham Partners Spring 2022 Investor Conference
RRMM: Incorporation of Selinexor into Clinical Practice
Potential Market for Actinium's Iomab-B
